Rhumbline Advisers raised its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.3% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 159,392 shares of the company’s stock after buying an additional 2,065 shares during the period. Rhumbline Advisers’ holdings in Henry Schein were worth $29,172,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HSIC. SpiderRock Advisors LLC acquired a new position in Henry Schein during the first quarter worth about $102,000. Lee Financial Co acquired a new position in Henry Schein during the second quarter worth about $161,000. JNBA Financial Advisors acquired a new position in Henry Schein during the first quarter worth about $170,000. Westside Investment Management Inc. acquired a new position in Henry Schein during the first quarter worth about $168,000. Finally, Peddock Capital Advisors LLC boosted its position in Henry Schein by 29.1% in the first quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock worth $186,000 after buying an additional 247 shares during the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Henry Schein, Inc. (HSIC) opened at 169.27 on Tuesday. The firm has a market capitalization of $13.38 billion, a PE ratio of 24.74 and a beta of 1.09. Henry Schein, Inc. has a 52-week low of $146.23 and a 52-week high of $186.99. The stock’s 50 day moving average price is $181.12 and its 200 day moving average price is $175.43.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.02. The business had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The company’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.64 EPS. On average, analysts predict that Henry Schein, Inc. will post $7.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Henry Schein, Inc. (NASDAQ:HSIC) Shares Bought by Rhumbline Advisers” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/henry-schein-inc-nasdaqhsic-shares-bought-by-rhumbline-advisers/1489703.html.

A number of research firms have issued reports on HSIC. Zacks Investment Research cut Henry Schein from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. BidaskClub cut Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Northcoast Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 target price for the company in a research note on Monday, August 7th. Jefferies Group LLC reissued a “hold” rating and issued a $177.00 target price on shares of Henry Schein in a research note on Friday, July 21st. Finally, Credit Suisse Group reissued a “hold” rating and issued a $160.00 target price on shares of Henry Schein in a research note on Thursday, July 13th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $185.56.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.